{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-035339","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.057724+00:00","generated_at":"2026-05-17T06:14:11.076982+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech reports 29.5-month median OS in low PD-L1 head and neck cancer cohort","bullets":["Median overall survival (mOS) of 29.5 months in CPS 1-19 cohort from VERSATILE-002 Phase 2 trial.","Published mOS for Keytruda monotherapy was 10.8 months; for Keytruda plus chemo 12.3 months.","Approximately 60% of trial patients (n=32) had low PD-L1 expression, a historically difficult-to-treat subset.","Data suggests PDS0101 + Keytruda may eliminate need for chemotherapy in this population."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-035339","json":"https://secwatch.observer/filing/0001140361-25-035339.json","markdown":"https://secwatch.observer/filing/0001140361-25-035339.md","text":"https://secwatch.observer/filing/0001140361-25-035339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/0001140361-25-035339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/ef20055698_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:14:11.076982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}